Inclisiran: A Novel Agent in the Management of Hypercholesterolemia

Q: What is the clinical evidence from this study?

Study design: Review. Population: Hypercholesterolemia and Atherosclerotic Cardiovascular Disease (ASCVD). Intervention: Inclisiran vs. Placebo or standard lipid-lowering therapy. Primary outcome: Low-density lipoprotein cholesterol (LDL-C) reduction.

Q: What does this research mean for the field?

Inclisiran is an effective therapeutic siRNA agent that lowers LDL-C levels by inhibiting hepatic PCSK9 translation via mRNA degradation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Loba Alam; Ali Aldamen; Namhee Kim; Sandra Maria Soler; Mahjabeen Rashid; David J. Harnick; Constantine E. Kosmas; Robert D. Fishberg; Timothy J. Vittorio

doi:10.52106/3066-3431.1020

October 8, 2026International Journal of Cardiology Research & ReviewsOpen Access

Inclisiran: A Novel Agent in the Management of Hypercholesterolemia

View Full Paper

Ask AI

Bookmark

Share

Key result

Twice-yearly inclisiran cuts LDL-C by ~50% in patients with ASCVD and hypercholesterolemia.

Why the study?

Current evidence regarding the role of inclisiran in the management of hypercholesterolemia needs to be discussed and summarized.

Does inclisiran safely and durably reduce LDL-C levels in patients with hypercholesterolemia and elevated cardiovascular risk?

Structured PICO

Does inclisiran safely and durably reduce LDL-C levels in patients with hypercholesterolemia and elevated cardiovascular risk?

P

Population

Patients with hypercholesterolemia across multiple clinical trials and real-world registries, including adults and adolescents with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents, heterozygous familial hypercholesterolemia (HeFH), and homozygous familial hypercholesterolemia (HoFH).

I

Intervention

Inclisiran (a small interfering RNA targeting hepatic PCSK9 production), typically administered as 300 mg subcutaneously on days 1, 90, and every 6 months thereafter.

C

Comparator

Placebo or PCSK9 monoclonal antibodies (alirocumab, evolocumab) on a background of standard lipid-lowering therapy (e.g., statins, ezetimibe).

O

Outcome

Reduction in low-density lipoprotein cholesterol (LDL-C) levels and PCSK9 levels.surrogate

This review summarizes extensive clinical trial and real-world evidence demonstrating that inclisiran is a highly effective, safe, and durable twice-yearly therapy for lowering LDL-C in high-risk patients.

Limitations

Definitive large-scale trials confirming the impact of inclisiran on major adverse cardiovascular events (MACE) are still ongoing.
Real-world data shows heterogeneous efficacy, particularly with attenuated LDL-C reductions observed in patients transitioning from prior PCSK9 monoclonal antibody therapy.
Lower magnitude of LDL-C reduction in real-world settings compared to ORION trial estimates
Attenuated and paradoxical responses observed when patients transition from prior PCSK9 monoclonal antibody therapy to inclisiran

Implication

May support convenient twice-yearly LDL-C control in hypercholesterolemia and ASCVD; leaves open dedicated cardiovascular outcome confirmation.

Abstract

PCSK9 is a serine protease that binds to the LDL receptors and targets the receptors for lysosomal degradation, thus reducing their recycling and decreasing the removal rate of circulating LDL-C. Monoclonal antibodies directed against PCSK9, such alirocumab and evolocumab, have been shown to cause a significant reduction in LDL-C levels and improve cardiovascular outcomes. On the other hand, inclisiran is a chemically synthesized siRNA molecule, which lowers LDL-C levels by targeting the hepatic production of PCSK9, as it prevents its translation via degradation of PCSK9 mRNA post-transcription. This review aims to discuss the current evidence regarding the role of inclisiran in the management of hypercholesterolemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alam et al. (2026) conducted a review in Hypercholesterolemia and Atherosclerotic Cardiovascular Disease (ASCVD). Inclisiran vs. Placebo or standard lipid-lowering therapy was evaluated on Low-density lipoprotein cholesterol (LDL-C) reduction. Inclisiran consistently achieves sustained LDL-C reductions of approximately 50% with a twice-yearly maintenance dosing regimen in patients with hypercholesterolemia and atherosclerotic cardiovascular disease.

synapsesocial.com/papers/6acf0f522fe143470d05867c https://doi.org/10.52106/3066-3431.1020

View Full Paper

Ask AI

Bookmark

Share

Inclisiran: A Novel Agent in the Management of Hypercholesterolemia

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Inclisiran: A Novel Agent in the Management of Hypercholesterolemia

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers